 iBio Inc NYSE: IBIO has provided an update on its IBIO-201 program and reported its progress in developing a second-generation subunit vaccine candidate, IBIO-202, being designed for the prevention of SARS-CoV-2 infection. IBIO-201 combines antigens derived from the spike protein S protein fused with iBios patented LicKM booster molecule 